FilingReader Intelligence
CARsgen Therapeutics cuts loss 79% as revenue hits RMB51m
August 14, 2025 at 02:40 PM UTC•By FilingReader AI
CARsgen Therapeutics reported a net loss of RMB75 million for the first half of 2025, down 79% from RMB352 million in 2024. Revenue reached RMB51 million with gross profit of approximately RMB29 million.
Cash and bank balances stood at RMB1.26 billion as of June 30, with the company expecting adequate cash until 2028.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:2171•Hong Kong Exchange
News Alerts
Get instant email alerts when CARsgen Therapeutics publishes news
Free account required • Unsubscribe anytime